Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Intangibles (2020 - 2026)

10x Genomics' Intangibles history spans 6 years, with the latest figure at $62.3 million for Q4 2025.

  • On a quarterly basis, Intangibles rose 297.73% to $62.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.3 million, a 297.73% increase, with the full-year FY2025 number at $62.3 million, up 297.73% from a year prior.
  • Intangibles hit $62.3 million in Q4 2025 for 10x Genomics, down from $64.8 million in the prior quarter.
  • Over the last five years, Intangibles for TXG hit a ceiling of $64.8 million in Q3 2025 and a floor of $200000.0 in Q4 2023.
  • Historically, Intangibles has averaged $24.1 million across 5 years, with a median of $22.3 million in 2023.
  • Biggest five-year swings in Intangibles: crashed 99.13% in 2023 and later skyrocketed 7735.5% in 2024.
  • Tracing TXG's Intangibles over 5 years: stood at $25.4 million in 2021, then fell by 10.0% to $22.9 million in 2022, then crashed by 99.13% to $200000.0 in 2023, then skyrocketed by 7735.5% to $15.7 million in 2024, then surged by 297.73% to $62.3 million in 2025.
  • Business Quant data shows Intangibles for TXG at $62.3 million in Q4 2025, $64.8 million in Q3 2025, and $14.7 million in Q2 2025.